iMDx to Release Third Quarter Results on November 16, 2026
Insight Molecular Diagnostics (Nasdaq: IMDX) will release third-quarter 2026 financial results after the market closes on November 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) will release third-quarter 2026 financial results after the market closes on November 16, 2026.
A live Zoom webinar with Q&A will follow at 2:00 pm PT / 5:00 pm ET. An archived replay will be available on the company’s website under Investors/Events & Presentations after the call concludes.
Details
Market move: IMDX -9.25% vs previous close. 3Q26 earnings report
On Nov 5, the day this news came out, the latest delayed price for IMDX is 9.25% below the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $2.40.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Scheduled results release
- November 16, 2026
- Third quarter 2026 results; after market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2026 financial results after the market closes on Monday, November 16, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.
The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDx Q3 2026 Earnings Webinar.
An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section.
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.
GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.
Investor Contact:
Alexandra Grossman
LifeSci Advisors LLC
imdx@lifesciadvisors.com
